Treating deadly lung disease, Breath Therapeutics is leading the 3rd phase with 43.5 million euros

Release date: 2017-03-14

Breath Therapeutics recently closed the A round of financing for 43.5 million euros. This round of financing was led by Gimv and Sofinnova Partners, and Gilde Healthcare is also involved. Breath Therapeutics, a company independent from PARI Pharma GmbH, also received financial support from PARI Pharma.

PARI Pharma is part of PARI Worldwide and is headquartered in Stamberg, Germany, with a focus on optimizing its advanced aerosol delivery platform. As an independent company, Breath Therapeutics has a phase 3 product of a combination of drugs and devices that can be used to treat a rare lung disease.

The product connects an inhaled formulation of an immunosuppressant to a remotely monitorable device, using an aerosolized form of liposomal cyclosporin A, which can be delivered by a nebulizer using remote monitoring techniques. This product is planned to evaluate the therapeutic effect of Bronchiolitis Obliterans Syndrome (BOS). BOS is a fatal respiratory disease that affects approximately 65% ​​of lung transplant patients. The product contains immunosuppressive agents that concentrate the drug in the lungs and are also the most needed.

The company plans to advance phase 3 clinical trials of the product in Europe and the United States and expects to submit the data directly to EMA and FDA.

“Our strategy is to place high concentrations of immunosuppressants directly into the small airways of the lungs,” said Dr. Jens Stegemann, head of business development at PARI and who will soon become Breath Therapeutics. “In the top investor community and With the support of the best international lung transplant center, we are now in a very good position to make a breakthrough in the fight against BOS."

â–² Dr. Jens Stegemann

“We are excited to participate in the Breath Therapeutics investment,” said Mr. Graziano Seghezzi, a partner at Sofinnova Partners. “We are impressed with the company’s talented and entrepreneurial team and its potential to break through the technology market. Sofinnova Partners has the strong expertise to turn an independent company into a successful company, and we are happy to share our experience and resources with the team to support the growth of Breath Therapeutics."

Reference material

[1] Breath Therapeutics spins out of PARI Pharma with $46 million and a ready-to-go phase III drug/device combo

Source: Chuangjianhui (WeChat Inno_Insight)

Hydraulic Power Unit

Hydraulic Power Unit,Hydraulic Pump Unit,Hydraulic Power Station,Power Unit,Hydraulic Poppet Valve,Hydraulic Pilot Valve

Changzhou Satidi Import and Export Co., Ltd. , https://www.guanjiejt.com